Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00368394
Other study ID # HMR1964/1019
Secondary ID HMR1964
Status Completed
Phase Phase 1
First received August 23, 2006
Last updated August 23, 2006
Start date January 2004

Study information

Verified date August 2006
Source Sanofi
Contact n/a
Is FDA regulated No
Health authority Germany: Paul-Ehrlich-Institut
Study type Interventional

Clinical Trial Summary

To investigate the dose-exposure-response relationship of insulin glulisine (HMR1964) after single subcutaneous injections of 0.075, 0.15 and 0.3 U/kg body weight with the euglycaemic clamp technique using the Biostator (TM).


Recruitment information / eligibility

Status Completed
Enrollment 18
Est. completion date
Est. primary completion date
Accepts healthy volunteers No
Gender Male
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria:

- Type 1 diabetes mellitus

Exclusion Criteria:

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment


Intervention

Drug:
Insulin glulisine


Locations

Country Name City State
Germany Sanofi-Aventis Neuss

Sponsors (1)

Lead Sponsor Collaborator
Sanofi

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Outcome measures: Glucose infusion rate, insulin concentrations.
Primary Outcome:In T1DM, glulisine, like RHI, displays dose proportionality in exposure over the dose range 0.075 to 0.3 U/kg, which partly only translates into dose proportionality in glucodynamics.
See also
  Status Clinical Trial Phase
Completed NCT00351234 - Carnitine Levels and Carnitine Supplementation in Type I Diabetes N/A
Recruiting NCT00875290 - The Effectiveness of Continuous Glucose Monitoring in Diabetes Treatment for Infants and Young Children Phase 3
Completed NCT00888628 - Study of Islet Transplantation in Type 1 Diabetic Kidney Transplant Recipients Phase 1/Phase 2
Completed NCT00147342 - The Effect of Insulin During Exercise on the Development of Low Blood Sugar in Individuals With Type I Diabetes N/A
Completed NCT00493935 - Effect of the Fat Content of the Bedtime Snack on Overnight Hypoglycemia N/A
Completed NCT00118976 - Maximal Dose of Angiotensin Converting Enzyme (ACE) Inhibitor for Treatment of Diabetic Kidney Disease N/A
Active, not recruiting NCT02081326 - Repeat BCG Vaccinations for the Treatment of Established Type 1 Diabetes Phase 2
Completed NCT00109434 - Study to Determine the Relationship Between Exercise and Hypoglycemia in Children With Type 1 Diabetes N/A
Withdrawn NCT00790439 - Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation After Kidney Transplant Phase 2
Completed NCT00789308 - Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation Phase 2
Completed NCT02970357 - Evaluation of the Impact of a Therapeutic Education Program for Children With Type 1 Diabetes N/A
Completed NCT02521675 - Validation of Algorithms for Basal Insulin Rate Reductions in Type 1 Diabetic Patients Practising Physical Activity in Real Life Conditions N/A
Completed NCT01781975 - Imatinib Treatment in Recent Onset Type 1 Diabetes Mellitus Phase 2
Terminated NCT04591925 - SteadiSetâ„¢ Pilot Study (SteP Study) N/A
Not yet recruiting NCT06147583 - Assessing Detection Algorithms for Insulin Pump Malfunctions in Type 1 Diabetes N/A
Active, not recruiting NCT00306098 - Islet Cell Transplantation Alone in Patients With Type 1 Diabetes Mellitus: Steroid-Free Immunosuppression Phase 2
Recruiting NCT05708820 - Online Education Programme for People With Type 1 Diabetes and Suboptimal Metabolic Control N/A
Completed NCT02556554 - Pilot Prospective CGM Quality Improvement (QI) Project in Pregnancy N/A
Completed NCT00652288 - Evaluation of Pharmacokinetics and Pharmacodynamic Properties of Rapid-Acting Insulin Analogs Phase 1

External Links